Tung, N. M., Zhao, F., DeMichele, A., Prat, A., Winer, E. P., Wright, J., Recht, A., Weiss, A., Tjoe, J. A., Feldman, S. M., Rocque, G. B., Smith, M. L., O'Sullivan, C. C., Sardesai, S. D., Villagrasa, P., Badve, S. S., Partridge, A. H., Miller, K., Carey, L. A., Wolff, A. C. (2025). Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.501